adenomas colorectal polyps/bowel cancer
Conditions
Interventions
Participants are invited to capsule endoscopy screening using the Pillcam colon
2/2L (Given Imaging ltd. Israel). Colon cleansing consists of a tablet
Bisacodyl 5 mg (Centrafarm BV) at bedtime 2 day
Norgine,
Amsterdam, The Netherlands) and 2 liter transparent fluid, split-dose. Booster
during CCE procedure consists of additional 250ml Eziclen boost and an optional
250ml Eziclen boost, each fol
it will take 5-10 minutes to complete one questionnaire.
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: All consecutive ambulatory patients referred for a colonoscopy at the Gastroenterology and Hepatology Department of the Erasmus MC because of a suspicion of colorectal polyps or colorectal cancer or a positive iFOBT after participation in a FOBT-based CRC screening trial will be eligible for participation.
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Inability or refusal to provide informed consent. - Persons with a severe or terminal disease with a life-expectancy of less than 5 years. - An allergy or any other known contraindication to the medication used in the study, including: - Renal failure, eGFR
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The pilot study will focus completely on testing of the quality of the CCE procedure as intended in the screening trial. The main study parameters are feasibility and logistical shortcomings, efficacy of bowel preparation and understandability of information material. | — |
Secondary
| Measure | Time frame |
|---|---|
| n.a. | — |
Countries
Netherlands
Outcome results
None listed